Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06157580 · ClinicalTrials.gov registry record · Early Phase 1
Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia
A Early Phase 1 study, sponsored by Anna Stanhewicz, PhD.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 24
- Enrollment target
NCT06157580 is a Early Phase 1 study that has completed, run by Anna Stanhewicz, PhD. The registered enrollment target is 24 participants.
The verdict
NCT06157580, a Early Phase 1 study, has completed, sponsored by Anna Stanhewicz, PhD.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Otherwise healthy women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during preeclampsia and persists postpartum, despite the remission of clinical symptoms. The purpose of this investigation is to determine the mechanisms contributing to this lasting blood vessel damage caused by reduced endothelial function in women who have had preeclampsia compared to women who had a healthy pregnancy. Identification of these mechanisms and treatment strategies may lead to better clinical management of cardiovascular disease risk in these women. The purpose of this study is to examine differences in the microvascular balance of angiotensin II receptors women who have had preeclampsia. This will help the investigators better understand the mechanisms of dysregulated angiotensin II receptors in formerly preeclamptic women, and how activation or inhibition of these receptors may restore microvascular function. In this study, the investigators use the blood vessels in the skin as a representative vascular bed for examining mechanisms of microvascular dysfunction in humans. Using a minimally invasive technique (intradermal microdialysis for the local delivery of pharmaceutical agents) the investigators examine the blood vessels in a dime-sized area of the skin.
Interventions
- DRUG Compound 21
- DRUG Angiotensin II
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2023-12-08 |
| Est. Completion | 2024-12-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06157580
The ClinicalTrials.gov registry entry for NCT06157580 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Anna Stanhewicz, PhD, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Compound 21 is the first listed.
NCT06157580 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06157580 about?
NCT06157580 is a clinical study titled "Balance of Angiotensin II Receptors in Vessel Function After Preeclampsia". Otherwise healthy women who develop preeclampsia during pregnancy are more likely to develop and die of cardiovascular disease later in life. The reason why this occurs is unclear but may be related to impaired endothelial function and dysregulation of the angiotensin system that occurs during preec...
What is the current status of trial NCT06157580?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 24 participants. The study started on 2023-12-08. Estimated completion is 2024-12-10.
What interventions are being tested in trial NCT06157580?
The interventions under investigation include: Compound 21 (DRUG), Angiotensin II (DRUG).
Who is sponsoring clinical trial NCT06157580?
This trial is sponsored by Anna Stanhewicz, PhD, which has 14 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.